Global COPD Market - by Type, Diagnosis, Treatment, Region - Market Size, Demand Forecasts, Industry Trends and Updates (2016-2022)

  • ID: 4425477
  • Report
  • Region: Global
  • 125 Pages
  • Oristep Consulting
25 % OFF
until Dec 31st 2018
1 of 5

FEATURED COMPANIES

  • Abbott
  • F. Hoffmann-La Roche Ltd
  • Galapagos NV
  • Merck
  • Novartis AG
  • Orexo
  • MORE

COPD, or chronic obstructive pulmonary disease is a group of progressive lung diseases of which the common ones are emphysema and chronic bronchitis. According to a new Global Burden of Disease study, it is estimated that chronic obstructive pulmonary disease caused 3.2 million deaths globally in 2015. Disease burden due to COPD was highest in Papua New Guinea, India, Lesotho, and Nepal. People working in occupations like Agriculture, Mining, Plastics, etc among others are more prone to be affected by COPD.

Demand Scenario

The global COPD market in 2016 was USD 13.7 billion and is estimated to reach USD 19 billion by 2022 at a CAGR of 5.6% during the forecasted period. Nucala and benralizumab will garner the North America sales, especially in the US.

Growth by Region

The major markets for the COPD are US, France, Germany, Italy, Spain, the UK, Japan, and Australia. In China, chronic respiratory diseases are the second leading cause of death.

Drivers vs. Constraints

Chronic obstructive pulmonary disease was the fifth cause of death in early years of 2000 and it is projected to be the fourth cause of mortality by 2025. Smoking is a major risk factor in men. In non-smoking women, unexpectedly, the prevalence of COPD is also high in high income countries, as well as in low and middle income countries. In low and middle income countries, COPD in women may be associated with biomass burning.

Industry Structure and Updates

High Prevalence of COPD will boost the Venturi Masks Market. AstraZeneca and GlaxoSmithKline (GSK) are the companies to focus on during the forecasted period s these have invested heavily in new products.

Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Abbott
  • F. Hoffmann-La Roche Ltd
  • Galapagos NV
  • Merck
  • Novartis AG
  • Orexo
  • MORE

1. Research Methodology

2. Executive Summary

3. Market Overview

  • Definition
  • Industry Value Chain Analysis
  • Porter's 5 Forces
  • Regulations

4. Market Dynamics

  • Introduction
  • Drivers
  • Constraints
  • Opportunities

5. Global COPD market Segmentation, Forecasts and Trends - by Revenue

6. By Type

  • Chronic Bronchitis
  • Emphysema

7. By Diagnosis

  • Spirometry
  • Diagnostic Tests
  • Chest X-Ray
  • Complete Blood Count
  • Others

8. By Treatment

  • Oxygen therapy
  • Lung transplant

9. By Region

  • North America
  • US
  • Canada
  • Europe
  • UK
  • France
  • Germany
  • Italy
  • Others
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Others
  • ROW

10. Vendor Market Share Analysis

11. Company Profiles

  • Abbott
  • AstraZeneca
  • F. Hoffmann-La Roche Ltd
  • Novartis AG
  • GSK
  • Roche
  • Mundipharma
  • Merck
  • Orexo
  • Nycomed
  • Galapagos NV
  • Forest Labs
  • Pfizer Inc
  • Dr. Reddy’s Laboratories Ltd
  • Others

12. Industry Structure

  • Industry M&As, Consolidations
  • Investment Opportunities

13. Global COPD market - Road Ahead

  • Tables
  • Disclaimer
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Abbott
  • AstraZeneca
  • Dr. Reddy’s Laboratories Ltd
  • F. Hoffmann-La Roche Ltd
  • Forest Labs
  • GSK
  • Galapagos NV
  • Merck
  • Mundipharma
  • Novartis AG
  • Nycomed
  • Orexo
  • Pfizer Inc
  • Roche
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll